HUMAN GENETICS • REVIEW

Nuclear genes involved in mitochondrial diseases caused by instability of mitochondrial DNA

Joanna Rusecka1 • Magdalena Kaliszewska1 • Ewa Bartnik1,2 • Katarzyna Tońska1

Received: 7 December 2017 / Accepted: 20 December 2017 / Published online: 17 January 2018
© The Author(s) 2018. This article is an open access publication

Abstract
Mitochondrial diseases are defined by a respiratory chain dysfunction and in most of the cases manifest as multisystem disorders with predominant expression in muscles and nerves and may be caused by mutations in mitochondrial (mtDNA) or nuclear (nDNA) genomes. Most of the proteins involved in respiratory chain function are nuclear encoded, although 13 subunits of respiratory chain complexes (together with 2 rRNAs and 22 tRNAs necessary for their translation) encoded by mtDNA are essential for cell function. nDNA encodes not only respiratory chain subunits but also all the proteins responsible for mtDNA maintenance, especially those involved in replication, as well as other proteins necessary for the transcription and copy number control of this multicopy genome. Mutations in these genes can cause secondary instability of the mitochondrial genome in the form of depletion (decreased number of mtDNA molecules in the cell), vast multiple deletions or accumulation of point mutations which in turn leads to mitochondrial diseases inherited in a Mendelian fashion. The list of genes involved in mitochondrial DNA maintenance is long, and still incomplete.

Keywords Mitochondrial diseases • Nuclear genes • Mitochondrial DNA instability • Mitochondrial DNA deletions • Depletion

The mitochondrion and its genome
Mitochondria are cytoplasmic organelles with a double phospholipid membrane and are present in almost all eukaryotic cells. Mitochondria are necessary for cell form and function. Their best recognized role is to generate energy by oxidative phosphorylation, but they also play a key role in synthesis of iron–sulfur centers, fatty acid oxidation, chemical signaling (Ca2+ signaling) and programmed cell death. The number of mitochondria in the cell varies and depends on the cell type and energy requirement, where cells with greater energy needs have more mitochondria than cells with smaller needs (Hudson and Chinnery 2006). Mitochondria are considered to be semi-autonomous, because in the course of evolution they have maintained their own small genome, known as mitochondrial DNA (mtDNA). The mitochondrial genome was discovered by Nass and Nass in 1963 (Nass and Nass 1963). In the same year, Schatz isolated mtDNA from Saccharomyces cerevisiae (Schatz 1963; Holt and Reyes 2012). mtDNA is required for production of key catalytic subunits of the mitochondrial respiratory chain complexes and therefore is essential for oxidative ATP production. In humans, it is a circular molecule of 16.5 kb carrying only 37 canonical genes. The mtDNA genes encode: 2 rRNAs, 22 tRNAs and 13 of 83 genes for respiratory chain subunits (MT-ATP6, MT-ATP8, MT-CO1, MT-CO2, MT-CO3, MT-CYB, MT-ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-ND6). Additionally, according to the newest discoveries, human mtDNA also encodes three short peptides, humanin, gau proteins and MOTS-c, with important biological functions, e.g., humanin plays a significant role in protecting neurons from apoptosis in Alzheimer’s disease (Shokolenko and Alexeyev 2015; Capt et al. 2016).

All other proteins (over 2000) required for the proper function of all mitochondrial biochemical pathways, including the rest of the subunits of respiratory complexes, are encoded by nuclear genes. This means that mitochondrial DNA expression, maintenance, copy number regulation, and repair
processes rely on the nuclear genome (Tyynismaa et al. 2005; Capps et al. 2003; DeBalsi et al. 2016; Scheibye-Knudsen et al. 2015).

Several features make mitochondrial DNA unique, for example in mammals it is maternally inherited (Chen et al. 2010). Moreover, there are up to thousands of mtDNA copies in each cell (Suomalainen and Isohanni 2010). When all the mtDNA molecules have the same sequence (wild or mutated) it is called homoplasmmy while heteroplasmmy implies the mixture of two or more types of mtDNA (for example wild type and mutant). The heteroplasmmy level of pathogenic variants correlates with the phenotype to some extent.

**Genetics of mitochondrial diseases**

Mitochondrial diseases are defined by a respiratory chain dysfunction and in most of the cases manifest as multisystem and multiorgan disorders with predominant expression in muscles and nerves. Generally, the prevalence of mitochondrial disease is around 1:10,000 and is similar to diseases like phenylketonuria or muscular atrophy but the exact frequencies vary between different populations and are not known for many of them. Prevalence of mitochondrial diseases is different in children (6.2:100,000) and adult patients (1:4300 affected or at risk) (Lightowlers et al. 2015). Moreover, the prevalence varies between populations of patients, e.g., prevalence of mitochondrial diseases in Spanish adult population (older than 14 years) is 5.7:100,000 (Arpa et al. 2003), in Australia 4.7:100,000 (Skladal et al. 2003).

Gorman et al. (2015) showed that mitochondrial disease is caused by mutations in nuclear genes in 2.9 per 100,000 adults in North East England.

Diseases caused by mtDNA mutations are maternally inherited, while those caused by mutations in nuclear genes encoding proteins more or less directly engaged in the function of the oxidative phosphorylation system (OXPHOS) are inherited in a Mendelian fashion (Wortmann et al. 2015). An interesting subgroup of mitochondrial disorders results from large deletions of mtDNA or its depletion. While single large mtDNA deletions occur spontaneously and are in most cases not transmitted from a mother to her children, multiple mtDNA deletions and depletion have Mendelian inheritance (Wong 2013; Dinwiddie et al. 2013; Lightowlers et al. 2015). The former is the result of the fact that the maintenance of mtDNA relies on proteins encoded in the nuclear genome.

Mitochondrial disorders associated with disturbed mtDNA stability (copy number and quality) are collectively called mitochondrial maintenance diseases or mtDNA depletion syndromes. The main feature of those disorders is rearrangement of the mitochondrial genome seen as multiple deletions of mitochondrial DNA molecules (the presence of multiple classes of mtDNA molecules of different lengths) and/or decrease of mtDNA copy number in cells, known as mtDNA depletion (Krishnan et al. 2008; Nicholls et al. 2014; Wong 2013; Gorman et al. 2015).

**Mitochondrial DNA maintenance**

Although mitochondrial DNA is not wound onto histone structures, it does not freely float in mitochondrial matrix. It is covered mainly by TFAM protein discovered as a transcription factor, but mainly engaged in forming the proper shape of the mitochondrial nucleoid and in copy number control (details later). The number of mtDNA molecules in one nucleoid is still being discussed — it seems to be one to a few. Obviously, replication plays the main role in the maintenance of mitochondrial DNA (Campbell et al. 2012).

**mtDNA replication machinery**

Initially, the strand displacement model (SDM) of replication was suggested but it was partially incorrect due to artifacts which occurred during the preparation process. An updated version of the SDM is called the RNA intermediate throughout the lagging-strand (RITOLS) model. Both models imply the presence of two origins of replication (ori, O), one on the heavy (H) strand and one on the light strand (L), called OH and OL respectively (Nicholls et al. 2014; Holt and Reyes 2012). OH is located within the non-coding region (NCR) of mtDNA, whereas OL is at two-thirds of the mtDNA length, within a cluster of tRNA genes. Replication starts from OH; polymerase adds nucleotides to an RNA primer and synthesis of the light strand starts only after OL has been reached. The main distinction is that the displaced maternal heavy strand is supposed to be naked in SDM and covered by short RNA fragments in the RITOLS model, but the main assumption, asynchronous replication, is common for both of them (McKinney and Oliveira 2013).

In 2000, Holt and colleagues proposed a new, synchronous model of mitochondrial DNA replication called COSCOFA (conventional strand–coupled Okazaki fragment associated). This model implies that synthesis is initiated bidirectionally from multiple origins of replication at ori zone (ori z). The leading H strand is synthesized continuously and the lagging L strand is formed without delay as Okazaki fragments (Holt et al. 2000).

It is suspected that different types of mitochondrial replication systems are present in various tissues or depend on the energy state of mitochondria and cells (Martín-García 2013).

The most important enzyme taking part in mtDNA replication is DNA polymerase gamma. Further proteins involved in this process are: Twinkle helicase, single-stranded DNA binding protein (mtSSB; may stabilize the displaced maternal H
Genes encoding proteins involved in mitochondrial DNA replication

The catalytic subunit of DNA polymerase gamma (encoded by the POLG gene) and its processivity factor (encoded by the POLG2 gene) together with Twinkle helicase (encoded by the TWNK gene), DNA replication helicase/nuclease 2 (encoded by the DNA2 gene), single-stranded DNA binding protein 1 (encoded by the SSBP1 gene), primase and polymerase (DNA-Directed) (encoded by the PRIMPOL gene), and mitochondrial genome maintenance exonuclease 1 (encoded by the MGME1 gene) play the key role in mitochondrial DNA maintenance and replication processes (Fig. 1).

POLG and POLG2 genes

One of the most important proteins encoded by the nuclear genome involved in replication, expression, maintenance, and repair of mitochondrial DNA is polymerase gamma (Poly). Poly is the only DNA polymerase involved in mtDNA replication present in the human mitochondrion (Garcia-Gòmez et al. 2013).

The holoenzyme is composed of a catalytic subunit POLG encoded by the POLG gene (15q26.1, 23,491 bp, 23 exons) and a homodimer of accessory subunits POLG2 encoded by the POLG2 gene (17q23.3, 26,283 bp, 8 exons) (Johnson and Johnson 2001; Oliveira et al. 2015; Hudson and Chinnery 2006).

POLG has a catalytic core with 3′-5′ exonuclease activity responsible for proofreading (26–418 amino acids), a linker domain (419–755 amino acids), and 5′-3′polymerase activity responsible for replication (756–1239 amino acids) (Oliveira et al. 2015; Hudson and Chinnery 2006).

The subunit encoded by the POLG gene is necessary for proper function of the enzyme, it enhances enzyme activity by simultaneously accelerating the polymerization rate and suppressing exonuclease activity (Szymanski et al. 2015; Johnson and Johnson 2001; Lee et al. 2009). Polymerase gamma is considered a high fidelity polymerase introducing less than 2 × 10⁻⁶ errors per nucleotide (Hudson and Chinnery 2006). POLG2 increases the affinity for DNA molecules (DiRe et al. 2009; Szymanski et al. 2015).

Mutations affecting polymerase gamma result in a wide range of genetic syndromes with many mtDNA mutations, deletions, multiple deletions, and depletion of mitochondrial DNA (Linkowska et al. 2015; Hudson and Chinnery 2006). Diseases associated with Poly dysfunction caused by mutations in the POLG gene include mitochondrial DNA depletion syndrome 4A (Alpers type, MIM 203700), a fatal infant disease with epilepsy and drug induced liver failure, mitochondrial DNA depletion syndrome 4B (MNGIE type, MIM 613662) with gastrointestinal involvement, mitochondrial recessive ataxia syndrome (includes SANDO and SCAE, MIM 607459), and relatively benign progressive external ophthalmoplegia autosomal dominant 1 (MIM 157640) and autosomal recessive 1 (MIM 258450) (Naïmi et al. 2006). All the above-mentioned diseases, which differ in severity and range of symptoms, may be caused by the same spectrum of POLG mutations. Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 4 (MIM 610131) develops as a result of mutations in the POLG2 gene.

TWNK

Polymerase γ cooperates with TWINKLE helicase (also known as PEO1) encoded by the T WN K gene (10q24.31, 11,866 bp, 6 exons). TWINKLE is a mitochondrial 5′-3′ helicase necessary for replication of human mitochondrial DNA (Mil enkovic et al. 2013; Tyynismaa et al. 2004). It binds to and unwinds double-stranded DNA (dsDNA) by breaking hydrogen bonds between annealed nucleotide bases and separating to single strands (Tyynismaa et al. 2005; Korhonen et al. 2003; Garcia-Gòmez et al. 2013; Cieskielski et al. 2016; Lamantea et al. 2002).

Mutations in the T WN K gene studied in cell cultures and deleter mice resulted in blocking of the replication process, accumulation of intermediates and finally in multiple mtDNA deletions (Goffart et al. 2009).

Known mutations result in insufficient mitochondrial DNA synthesis and lead to deletions and depletion of mtDNA (Nikkanen et al. 2016; Paramasivam et al. 2016). They are a frequent cause of progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 3 (MIM 609286) but in rare cases may lead to recessive diseases like mitochondrial DNA depletion syndrome 7 (hepatocerebral type) (MIM 271245) and Perrault syndrome 5 (MIM 616138).

SSBP1

Stabilization of the replication fork through preventing binding strands of a replicated fragment of DNA from forming secondary structures and degradation is the main role of single stranded DNA binding protein 1 (SSBP1) encoded by the SSBP1 gene (7q34, 12,180 bp, 9 exons). SSBP1 interacts with polymerase gamma and helicase Twinkle and strengthens
Their functions (Hudson and Chinnery 2006; Ruhanen et al. 2010).

Studies on Saccharomyces cerevisiae RIMI null mutants (RIMI encodes ssDNA binding protein) (Van Dyck et al. 1992) and mutants in the lopo (low power) gene from Drosophila melanogaster (which affect the mitochondrial single-stranded DNA-binding protein) (Maier et al. 2001) showed depletion of mitochondrial DNA and confirmed that this protein is necessary for replication and maintenance of mtDNA. In HeLa cell cultures with silenced SSBP1 the mtDNA/nDNA ratio decreased and synthesis of the D-loop was affected (Ruhanen et al. 2010). No pathogenic variants in this gene have been described.

PRIMPOL

The PRIMPOL gene (4q35.1, 52,347 bp, 16 exons) encodes nuclear and mitochondrial primase and DNA directed polymerase. PRIMPOL plays a key role in mtDNA replication initiation. Moreover, it enables the replication machinery to replicate past DNA lesions (translesion synthesis, TLS), e.g., in apurinic/apyrimidinic sites (AP sites). This protein is present both in the nucleus and mitochondria. Silencing of the PRIMPOL gene in human fibroblasts leads to multiple mtDNA deletions and depletion. A PRIMPOL mouse knockout is viable but mtDNA replication deficiency is observed on the cellular level. This confirms that absence of PRIMPOL has multiple adverse effects on mtDNA synthesis (García-Gómez et al. 2013). Mutations in this gene have been shown to result in autosomal dominant myopia (type 22, MIM 615420).

DNA2

A member of the DNA2/NAM7 helicase family, DNA2 is a DNA replication helicase/nuclease 2 enzyme encoded by the DNA2 gene (10q21.3, 58,458 bp, 22 exons). It has nuclease, helicase, and ATPase activity and interacts with polymerase gamma by stimulating its catalytic activity. DNA2 removes RNA primers and stabilizes mtDNA structure during the replication process; thus, playing an important role in the maintenance of mitochondrial DNA. Moreover, DNA2 participates in repair of small DNA lesions induced by oxidation, alkylation or spontaneous hydrolysis and is critical for long-patch base-excision repair (LP-BER) (Ronchi et al. 2013).

Mutations in DNA2 are associated with recessive Seckel syndrome 8 (MIM 615807) and dominant progressive external ophthalmoplegia with mitochondrial DNA deletions (MIM 615156).

Fig. 1 Mitochondrial DNA instability types with their molecular backgrounds and diseases they cause. AR – autosomal recessive, AD – autosomal dominant

Table: Mitochondrial DNA instability types with their molecular backgrounds and diseases they cause.

| Diseases | Type of mtDNA instability | Genes encoding proteins involved in mtDNA replication | Genes encoding proteins involved in nucleotide metabolism | Other genes |
|----------|---------------------------|------------------------------------------------------|--------------------------------------------------------|-------------|
| Kearns-Sayre syndrome | Single mtDNA deletion | POLG (AR, AD) | MPV17 (AR) |
| Pearson syndrome | Multiple mtDNA deletions | POLG2 (AD) | DNA2 (AR) |
| Progressive external ophthalmoplegia (PEO) and PEO+ | Depletion | TWHK (AD) | TYMP (AR) |
| Leigh syndrome (mtDNA deletion) | | | |

Fig. 1 Mitochondrial DNA instability types with their molecular backgrounds and diseases they cause. AR – autosomal recessive, AD – autosomal dominant.
MGME1

The *MGME1* gene (20p11.23, 22,529 bp, 8 exons) encodes mitochondrial genome maintenance exonuclease 1 (MGME1) protein probably involved in mtDNA repair (Uhler et al. 2016).

MGME1 removes flaps (last 20–50 nt) during replication and enables the processing of mtDNA ends due to the ability to cleave dsDNA in both 5'–3' and 3'–5' directions. Thus this exonuclease can cut 5' and 3' flaps. Moreover, MGME1 may enhance exonuclease activity of polymerase gamma (Nicholls et al. 2014; Uhler et al. 2016).

Studies on human fibroblast culture with null *MGME1* show that the absence of MGME1 leads to large mtDNA rearrangements such as deletions and depletion. Significant shortening of the D-loop leading to incorrect processing of the mtDNA 5'end was observed as well (Nicholls et al. 2014).

*MGME1* loss-of-function mutations lead to mitochondrial disease with DNA depletion, deletions, duplications, and rearrangements and result in mitochondrial DNA depletion syndrome 11 (MIM 615084).

RNASEH1

Ribonuclease H1, encoded by the *RNASEH1* gene (2p25.3, 33,559 bp, 14 exons) is an endonuclease involved in DNA replication and repair processes both in the nucleus and mitochondria, but in mitochondria it is the only ribonuclease of that type while in the nucleus there are two (besides ribonuclease H2). Ribonuclease H1 specifically digests double-stranded DNA-RNA hybrids and is necessary to produce primers for mtDNA replication.

It was shown, both in mice and human, that loss of RNaseH1 activity disturbs mtDNA replication. In mice, a knockout of *Rnaseh1* leads to embryonic lethality with mtDNA depletion (Cerritelli et al. 2003). In human, mutations in *RNASEH1* have been recently attributed to autosomal recessive PEO with mtDNA deletions (MIM 616479) (Reyes et al. 2015).

Genes encoding proteins involved in transcription of mtDNA

The transcription machinery is not only essential for gene expression but also mtDNA copy number regulation as it is responsible for the synthesis of the primers for replication. Mitochondrial RNA polymerase POLRMT and a set of transcription factors: TFAM, TEFM, and TFB2M are responsible for that process.

The human mitochondrial genome contains two transcription promoters: LSP and heavy-strand promoter 1 (HSP1) and HSP2 (Lodeiro et al. 2012). Initiation of transcription from HSP promoter is only POLRMT dependent. POLRMT generates short RNA primers near oriL (during the replication process this region becomes single stranded and forms a loop structure). Efficient initiation of transcription from LSP requires cooperative action of POLRMT and transcription factors TFAM and TFB2M (Littonin et al. 2010).

POLRMT

Mitochondrial RNA polymerase encoded by the *POLRMT* gene (19p13.3, 23,346 bp, 21 exons) is responsible for transcription of the mitochondrial genome and also provides primers for mtDNA replication, therefore all changes in the enzyme structure (or transcription complex) may impact mtDNA stability. POLRMT together with TFAM, TEFM, and TFB2M forms a transcription complex (Kühl et al. 2016; Posse et al. 2015; Minczuk et al. 2011).

TFB1M and TFB2M interact directly with POLRMT, help in promoter recognition, and increase transcription efficiency 100–200-fold as compared with RNA polymerase alone (Falkenberg et al. 2002; Littonin et al. 2010).

TFAM

*TFAM* (10q21, 14,088 bp, 9 exons) is the mitochondrial transcription factor A coding gene also known as *TCF6L3* or *mtTFA*. TFAM is a key activator of mitochondrial transcription, plays an important role in mitochondrial DNA replication and copy number regulation, and is crucial for mitochondrial biogenesis. TFAM expression and turnover depends on the interaction between POLRMT, TFAM, and mitochondrial DNA (Picca and Lezza 2015; Kang et al. 2007; Ekstrand et al. 2004). In vitro experiments show that equimolar amounts of TFAM and mtDNA template result in the maximal transcription level (Littonin et al. 2010). Change in TFAM expression results in change of the protein level and influences mtDNA copy number (it is directly proportional). A mutation in the TFAM gene has been recently described as a cause of neonatal liver failure with mtDNA depletion (Stiles et al. 2016).

TEFM

The mitochondrial transcription elongation factor encoded by the *TEFM* gene (17q11.2, 7933 bp, 4 exons) is responsible for transcript elongation. TEFM forms a complex with mitochondrial RNA polymerase, interacts with its catalytic domain, enhances processivity (Minczuk et al. 2011), and probably regulates the DNA replication initiation process (Posse et al. 2015). It was shown that when TEFM is absent in a mitochondrial transcription machinery model transcription is terminat-ed and total transcript levels were significantly lower and transcripts were shorter. This indicates that TEFM is essential for full-length mtDNA transcript formation (Posse et al. 2015).
TFB2M

Mitochondrial transcription factor B2, also known as mitochondrial 12S rRNA dimethylase 2 or mitochondrial dimethyladenosine transferase 2 mtTFB2, encoded by the TFB2M gene (1q44, 25,703 bp, 8 exons) is a part of the mtDNA transcription complex (Moustafa et al. 2015).

Mutations in POLMRT, TEFM, and TFB2M have not been described yet but changes in their expression may cause mitochondrial DNA instability and could lead to mitochondrial disease.

Genes encoding proteins involved in nucleotide metabolism

Balance in free nucleotide concentrations is very important for proper DNA replication. It is particularly important in mitochondria, because there are no de novo nucleotide biosynthesis pathways. Mitochondria rely mainly on salvage pathways localized partially in mitochondria and partially in the cytoplasm. Imbalance in free nucleotide concentrations leads to disturbances in mtDNA replication and in consequence to mtDNA copy number decrease or to the appearance of multiple deletions.

There are two deoxyribonucleoside kinases expressed in mitochondria phosphorylating purine and pyrimidine deoxyribonucleosides. Thymidine kinase-2 (TK2) phosphorylates deoxythymidine, deoxycytidine, and deoxyuridine, while deoxyribonucleoside kinase (dGK) phosphorylates deoxyguanosine and deoxyadenosine (Saada et al. 2001).

The RRM2B gene encodes a protein participating in catalytic conversion of ribonucleoside diphosphates (NDP) to deoxyribonucleoside diphosphates (dNDP) – basic elements for DNA synthesis (Pontarin et al. 2012).

TK2

The TK2 gene (16q21, 42,410 bp, 12 exons) encodes a mitochondrial matrix enzyme – thymidine kinase 2 (TK2). TK2 is an enzyme essential for mtDNA maintenance, catalyzes the rate-determining step of the pyrimidine salvage pathway (Tyynismaa et al. 2012) and generates (by phosphorylation) thymidine monophosphate (TMP), cytidine monophosphate (CMP) and deoxyuridine from deoxypirimidine nucleosides (Cámara et al. 2015; Saada et al. 2001).

Mutations in the TK2 gene result in a decrease of enzyme activity which impairs recycling of mtDNA nucleotides and finally causes progressive muscle weakness (myopathy) and mitochondrial DNA depletion syndrome 2 (myopathic type, MIM 609560) (Cámara et al. 2015; Saada et al. 2001; Wang et al. 2003).

Approximately 30 pathogenic mutations in the TK2 gene have been described (ClinVar) with a hot spot in exon 5 (Manusco et al. 2003).

For example, Cámara et al. (2015) observed that compound mutations in the TK2 gene (p.T108 M and p.K202del) were present in DNA isolated from muscle biopsies from patients with myopathy. They also observed a dramatic decrease of mtDNA copy number in cells. Structural analysis of the enzyme showed that missense mutations were linked with binding affinities of dTMP and dCTP (Cámara et al. 2015). Mutation p.T108 M was also described by Behin et al. (2012) and Paradas et al. (2013) and was associated with a 30% depletion of mtDNA and deletion of 45% of mtDNA molecules when compared to controls.

DGUOK

Deoxyguanosine kinase (dGK), another matrix enzyme, encoded by the DGUOK gene (2p13, 32,136 bp, 8 exons) provides phosphorylated purines necessary for mtDNA synthesis (Jullig and Eriksson 2000; Ronchi et al. 2012). Mutations in this gene lead to mitochondrial DNA depletion syndrome 3 (hepatocerebral type) (MIM 251880).

In silico analysis suggested that the most frequent mutations in the gene affect the structure of dGK. Biochemical analysis of the activity of dGK isolated from skeletal muscles from myopathic patients showed that mutations may impair the enzyme function (Ronchi et al. 2012).

RRM2B

RRM2B gene (8q22.3, 34,618 bp, 9 exons) encodes ribonucleotide reductase regulatory TP53 inducible subunit M2B (p53R2), a part of ribonucleotide reductase. This cytoplasmic enzyme is responsible for conversion of ribonucleoside diphosphates to deoxyribonucleoside diphosphates and is an element of the de novo nucleotide biosynthesis pathway. Ribonucleotide reductase is composed of large R1 and small R2 subunits. There are two types of R2 subunits in the cell. One is present during the S phase of the cell cycle only, the second one, encoded by RRM2B, provides the basal level of deoxyribonucleoside diphosphates. mtDNA replication, generally independent of cell cycle, takes place not only during the S phase, p53R2 protein is crucial for mtDNA synthesis.

Mutations in RRM2B lead to mtDNA depletion (Pontarin et al. 2012).

Diseases associated with mutations in the RRM2B gene include mitochondrial DNA depletion syndrome 8A (encephalomyopathic type with renal tubulopathy) (MIM 612075), mitochondrial DNA depletion syndrome 8B (MNGIE type) (MIM 612075), and progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 5 (MIM 613077).
TYMP

Thymidine phosphorylase (TP) is another protein important for nucleotide biosynthesis encoded by the *TYMP* gene (22q13.33, 4334 bp, 10 exons). This cytosolic enzyme of the salvage pathway catalyzes the cleavage of thymidine into thymine and 2-deoxy-α-D-ribose-1-phosphate and plays an important role in catabolic processes (Javaida et al. 2016). TP is also considered a promoter of tumor growth and metastasis. Overexpression prevents apoptosis and induces angiogenesis and is associated with tumor aggressiveness and poor prognosis (Bronckaers et al. 2009).

Mutations in *TYMP* lead to accumulation of nucleosides and an imbalance in the mitochondrial nucleotide pool and results in MNGIE type autosomal recessive mitochondrial DNA depletion syndrome 1 (MIM 603041) (Table 1).

SLC25A4

The *SLC25A4* gene (4q35.1, 7144 bp, 4 exons) encoding a heart muscle specific isoform of a solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator) member 4 also known as *ANT1* was the first gene in which mutations responsible for mtDNA instability were described (Kaukonen et al. 2000). The gene product (monomer protein) forms a pore at the mitochondrial inner membrane. ANT1 predominates in post-mitotic tissues such as muscles and heart (Pebay-Peyroula et al. 2003; Ahmed et al. 2015). ANT1 regulates ATP and ADP transport — it transfers ADP from the cytoplasm to the mitochondrial matrix and ATP from the matrix to the cytoplasm (Neckelmann et al. 1987; Kawamata et al. 2011). The exact mechanism of mtDNA destabilization by the *SLC25A4* mutations is not known. Definitely, the ADP/ATP balance is important for maintenance of the membrane potential. It is also postulated that ATP and ADP concentration may influence dATP quantity and also affect proper DNA/RNA hybrid formation during replication.

Most of the described *SLC25A4* mutations cause misfolding of the protein and affect intermembrane exchange of molecules leading to inhibition of cell growth. Moreover, the changed ANT1 protein interacts with other membrane proteins and affects their function (Liu et al. 2015).

Mitochondrial DNA instability was shown in *SLC25A4* knockout mice (Krishnan et al. 2008).

Mutations in *SLC25A4* can be inherited in an autosomal dominant or recessive manner. Dominant mutations leading to progressive external ophthalmoplegia with mitochondrial DNA deletions (PEO) (MIM 609283) seem to show a dominant-negative effect on the molecular level, while the phenotype caused by recessive ones (mitochondrial DNA depletion syndrome 12 (cardiomyopathic type)) (MIM 615418) is more similar to the one obtained for knockout mice.

**Genes encoding proteins involved in mitochondrial fusion, fission, and mobility**

Mitochondria are no longer considered as static bean-shaped structures. They move, fuse, and divide and form a network interconnected with the endoplasmic reticulum. Undisturbed fusion, fission, and movement are especially important in neurons, where mitochondria have to travel along axons and dendrites to act in the proper time and place. Fusion and fission are energy dependent so they rely on effective respiration and at the same time quality control of mitochondria is based on fusion and fission. Defects in fusion, as proven in detail in mice, lead to loss of mtDNA copy number, multiple mtDNA deletions, and increase the point mutation rate (Chen et al. 2010).

Genes involved in mitochondrial fusion and fission most frequently mentioned in the context of human disease include *OPA1* (mitochondrial dynamin like GTPase), *MFN1* (mitofusin 1), and *MFN2* (mitofusin 2) encoding proteins involved in fusion, *FIS1* (mitochondrial fission 1 protein), *DNM1L* (dynamin 1-like protein, Drp1), and *MFF* (mitochondrial fission factor) important for proper mitochondrial division (MacVicar and Langer 2016; Losón et al. 2013).

**OPA1**

The *OPA1* (3q29, 104,668 bp, 32 exons) gene encodes mitochondrial dynamin like GTPase. OPA1 plays an important role in mtDNA maintenance, mutations in the *OPA1* gene lead to mtDNA multiple deletions (Hudson et al. 2007). OPA1 protein localizes to the inner mitochondrial membrane where it is involved in cristae formation and proper fusion of the inner membrane. One of the OPA1 isoforms localizes in the nucleoid and seems to be involved in mtDNA replication (Yu-Wai-Man et al. 2010; Elachouri et al. 2011).

More than 200 mutations in the *OPA1* gene have been found of both autosomal dominant and autosomal recessive character. They are associated with autosomal dominant optic atrophy 1 (MIM 165500), optic atrophy plus syndrome (MIM 125250) and autosomal recessive Behr syndrome (MIM 210000). In one consanguineous family, mitochondrial DNA depletion syndrome 14 (encephalomyocardiomyopathic type) (MIM 616896) due to a homozygous *OPA1* mutation has been described.

**MFN1**

The *MFN1* gene (3q26.33, 47,253 bp, 17 exons) encodes a transmembrane GTPase localized in the mitochondrial outer membrane. MFN1 (mitofusin 1) forms homomultimers and heteromultimers with MFN2 (mitofusin 2) and together they are responsible for outer mitochondrial membrane fusion. There are no human diseases attributed to *MFN1* mutations.
| Gene       | Localization | MIM number | Disease                                                                 | Inheritance | Phenotype                                                                 | Age of onset |
|------------|--------------|------------|-------------------------------------------------------------------------|-------------|---------------------------------------------------------------------------|--------------|
| MNF2       | 1p36.22      | 609,260    | Charcot-Marie-Tooth disease, axonal, type 2A2A (CMT2A2A)               | AD          | CMT disease is a group of progressive neurologic disorders characterized by peripheral neuropathy and optic atrophy. Damage of the peripheral nerves results in loss of sensation (touch, pain, heat, and sound) and muscle weakness in the feet, legs, and hands | infancy      |
| MNF2       | 1p36.23      | 617,087    | Charcot-Marie-Tooth disease, axonal, type 2A2B (CMT2A2B)               | AR          | Disease is a group of progressive neurologic disorders characterized by peripheral neuropathy and optic atrophy. Damage of the peripheral nerves results in loss of sensation (touch, pain, heat, and sound) and muscle weakness in the feet, legs, and hands | infancy      |
| DGUOK      | 2p13.1       | 251,880    | Mitochondrial DNA depletion syndrome 3 (hepatic type)                  | AR          | Genetic disorder characterized by multisystemic neurological abnormalities including muscle weakness, PEO, liver failure and lactic acidosis | infancy      |
| DGUOK      | 2p13.2       | 617,068    | Portal hypertension, noncirrhotic                                       | AR          | Disorder, relatively benign, is characterized by onset of high blood pressure in the hepatic portal system associated with hepatosplenomegaly. | childhood or adulthood |
| DGUOK      | 2p13.3       | 617,070    | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 4 | AR          | Disorder characterized by adult onset of eye muscle weakness and proximal limb muscle weakness | adulthood    |
| MPV17      | 2p23.3       | 256,810    | Mitochondrial DNA depletion syndrome 6 (hepatic type)                  | AR          | Infantile onset disorder which affects liver and muscles.               | infancy      |
| RNASEH1    | 2p25.3       | 616,479    | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 2 | AR          | Disorder characterized by adult onset of PEO, proximal limb muscle weakness and symptoms of spinocerebellar ataxia | adulthood    |
| MFF        | 2q36.3       | 617,086    | Encephalopathy due to defective mitochondrial and peroxisomal fission 2 | AR          | Encephalopathy, including delayed psychomotor development, hypotonia and muscle weakness | childhood    |
| OPA1       | 3q29         | 616,896    | Mitochondrial DNA depletion syndrome 14 (encephalocardiomyopathic type) | 0           | Encephalopathy, cardiomyopathy.                                          | infancy      |
| PRIMPOL    | 4q35.1       | 615,420    | Myopia 22, autosomal dominant                                          | AD          | Optic atrophy associated with neurological manifestations including myoclonic epilepsy, progressive spastic paraplegia, dysarthria, extra-pyramidal tract signs, ataxia, urinary incontinence, mental retardation, posterior column sensory loss or muscle contractures (predominant in the lower limbs) | early childhood |
| SLC25A4    | 4q35.1       | 617,184    | Mitochondrial DNA depletion syndrome 12A (cardiomyopathic type)        | AD          | Disorders characterized by cardiomyopathy or hypertrophic cardiomyopathy and muscle weakness | infancy      |
| SLC25A4    | 4q35.2       | 615,418    | Mitochondrial DNA depletion syndrome 12B (cardiomyopathic type)        | AR          | Disorers characterized by cardiomyopathy or hypertrophic cardiomyopathy and muscle weakness | childhood    |
| SLC25A4    | 4q35.3       | 609,283    | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 2 | AD          | Disorder characterized by weakness of the external eye muscles, limb muscle weakness and exercise intolerance | adulthood    |
| Gene | Localization | MIM number | Disease | Inheritance | Phenotype | Age of onset |
|------|--------------|------------|---------|-------------|-----------|-------------|
| RRM2B | 8q22.3 | 612,075 | Mitochondrial DNA depletion syndrome 8A (encephalomyopathic type with renal tubulopathy) | AR | Mitochondrial neurogastrointestinal encephalopathy (MNGIE). Disease affects the digestive and nervous system | infancy |
| | 8q22.4 | 612,075 | Mitochondrial DNA depletion syndrome 8B (MNGIE type) | AR | | |
| | 8q22.5 | 613,077 | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 5 | AD | Autosomal dominant progressive external ophthalmoplegia (adPEO) | adulthood |
| TFAM | 10q21.1 | 617,156 | Mitochondrial DNA depletion syndrome 15 (hepatocerebral type) | AR | First symptoms occur at or soon after birth including hypoglycemia, hyperbilirubinemia, jaundice etc. | infancy |
| DNA2 | 10q21.3 | 615,807 | Seckel syndrome 8 | AR | Also known as bird-headed dwarfism, disorder characterized by growth and mental retardation | infancy |
| | 10q21.4 | 615,156 | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 6 | AD | Adult onset PEO with limb-girdle muscle weakness predominantly affecting the lower limb | childhood or adulthood |
| TWNK | 10q24.31 | 271,245 | Mitochondrial DNA depletion syndrome 7 (hepatocerebral type) | AR | Neurodegenerative disease characterized by hypotonia, ataxia, ophthalmoplegia, hearing loss, seizures, and sensory axonal neuropathy | childhood or adulthood |
| | 10q24.32 | 616,138 | Perozult syndrome 5 | AR | Neurological disorder with a characteristic feature of hearing loss caused by abnormalities in the inner ear | childhood |
| | 10q24.33 | 609,286 | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 3 | AD | Clinical features of this disease include adult onset of weakness of the external eye muscles and exercise intolerance | adulthood |
| DNM1L | 12p11.21 | 614,388 | Encephalopathy, lethal, due to defective mitochondrial peroxisomal fission 1 | AD, AR | Encephalopathy with hypotonia and delayed psychomotor development | childhood |
| POLG | 15q26.1 | 203,700 | Mitochondrial DNA depletion syndrome 4A (Alpers type) | AR | Alpers syndrome is the clinical triad of psychomotor retardation, intractable epilepsy, and liver failure in infants and young children | infancy to young children |
| | 15q26.2 | 613,662 | Mitochondrial DNA depletion syndrome 4B (MNGIE type) | AR | Progressive multisystem disorder clinically characterized by chronic gastrointestinal dysmotility, PEO, axonal sensory ataxic neuropathy and muscle weakness | childhood or adulthood |
| | 15q26.3 | 607,459 | Mitochondrial recessive ataxia syndrome (includes SANDO and SCAE) | AR | SANDO is characterized by sensory ataxic neuropathy, dysarthria, and ophthalmoparesis. | adulthood |
| | 15q26.4 | 157,640 | Progressive external ophthalmoplegia, autosomal dominant 1 | AD | PEO and muscle weakness, may include hearing loss, ataxia and parkinsonism | adulthood |
| | 15q26.5 | 258,450 | Progressive external ophthalmoplegia, autosomal recessive 1 | AR | | adulthood |
| TK2 | 16q21 | 617,069 | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 3 | AR | Adult-onset progressive external ophthalmoplegia, sometimes with progressive proximal muscle weakness | adulthood |
| | 16q22 | 609,560 | Mitochondrial DNA depletion syndrome 2 (myopathic type) | AR | Childhood onset of muscle weakness and a slowly progressive myopathy | infancy or childhood |
| SPG7 | 16q24.3 | 607,259 | Spastic paraplegia 7 | AD, AR | Disease characterized by spasticity of limbs sometimes with additional neurologic features | adulthood |
Similar to *MFN1*, the *MFN2* gene (1p36.22, 33,335 bp, 19 exons) encodes a transmembrane GTPase localized in the mitochondrial outer membrane and shares high homology with *MFN1*. Two transcriptional forms are known. Mitofusin 2 was described as a protein enabling close contact of mitochondria with the endoplasmic reticulum. Recently the opposite was found: depletion of MFN2 results in a closer contact with ER (Filadi et al. 2015).

Mutations in *MFN2* are the main cause of autosomal dominant Charcot-Marie-Tooth disease, axonal, type 2A2A (MIM 609260) but also autosomal dominant hereditary motor and sensory neuropathy VIA (MIM 601152) and autosomal recessive Charcot-Marie-Tooth disease, axonal, type 2A2B (MIM 617087). mtDNA depletion and multiple deletions were observed in muscles and fibroblasts from patients with AD Charcot-Marie-Tooth disease caused by *MFN2* mutations (Vielhaber et al. 2013).

**DNM1L**

The *DNM1L* (12p11.21, 66,451 bp, 21 exons) encodes another member of the GTPase family: dynamin-1-like protein which regulates mitochondrial function and plays a crucial role in the division, fusion, and fission of mitochondria. DNM1L forms an oligomeric ring at the division spot that narrows and splits the mitochondrial tubule (Fahrner et al. 2016). DNM1L is critically important in human (and general mammalian) development, its absence causes abnormality in embryonic development. Nonsense mutations disturb central nerve system development. Yoon et al. (2016) have shown that if mutations were present in the *DNML* gene, giant mitochondria with an abnormal shape were present in neurons in human (with compound heterozygous mutations in *DNM1L* gene) and knock-out mice. Mutations in the DNM1L gene cause encephalopathy which is lethal due to defective mitochondrial and peroxisomal fission (type 1) (MIM 614388, autosomal dominant).

**MFF**

The *MFF* gene encodes the mitochondrial fission factor (2q36.3, 32,686 bp, 13 exons), which is an outer membrane protein required for localization of DNM1L and division of mitochondria. MFF protein together with FIS1 are responsible for recruitment of DNM1L to the division site (Friedman et al. 2011). Mutations in *MFF* lead to a similar phenotype to DNM1L mutations (encephalopathy, lethal, due to defective mitochondrial and peroxisomal fission 2, autosomal recessive).
FIS1

FIS1 – tetratricopeptide repeat domain-containing protein 11 encoded by the FIS1 gene (7q22.1, 5479 bp, 5 exons) acts independently of MFF. No diseases caused by FIS1 mutations have been described.

Miscellaneous

Besides the above-mentioned genes encoding proteins involved in the processes with more or less well described influence on mtDNA stability, there are multiple other genes not involved in any of these processes in which mutations lead to mtDNA deletions or depletion. Here we mention only a few of them with the highest impact on human health.

MPV17

Although MPV17 (2p23.3, 13,611 bp, 9 exons) mutations were described as a cause of autosomal recessive mitochondrial depletion syndrome ten years ago (Spinazzola et al. 2006), the function of the protein encoded by this gene was not known. Recently (Antonenkov et al. 2015), this inner membrane protein was shown to function as a non-selective channel under a strict control of factors reflecting the energetic state of mitochondria such as membrane potential or redox state.

SPG7

The SPG7 gene (16q24.3, 66,852 bp, 22 exons) encodes paraplegin which is a component of the mitochondrial AAA protease. Spastic paraplegia 7 takes part in many cellular functions like ribosome assembly regulation, membrane trafficking, protein folding, intracellular motility, organelle biogenesis, and proteolysis. Mutations in SPG7 historically have been attributed to spastic paraplegia 7, autosomal recessive (MIM 607259) but recently were found to be an important factor in mitochondrial diseases (Sánchez-Ferrero et al. 2013; Pfeffer et al. 2014; Gorman et al. 2015). Mutations in that gene lead to chronic progressive external ophthalmoplegia due to disordered mitochondrial DNA maintenance. In the North East England population prevalence of mutations in the SPG7 gene is greater than in TWNK, OPA1, and POLG genes (Pfeffer et al. 2015; Gorman et al. 2015).

As we mentioned at the beginning of this review, mitochondrial diseases are very difficult to diagnose due to complex genotype–phenotype relationships, also called a blended phenotype. This means that mutations in one gene can lead to different clinical phenotypes and mutations in different genes
can lead to the same signs and symptoms (Wortmann et al. 2015).

Phenotype

Mitochondrial diseases affect each individual differently. Although mitochondrial disease primarily affects children, adult onset is becoming more common (Fig. 2).

Summary

Mitochondrial diseases are a heterogeneous group of diseases. Age of onset is very different, from infants to the fifth decade of life. Symptoms involve multiple tissues and most of them may be progressive. Genetic background of this group of diseases is still unknown. The list of genes involved in mitochondrial DNA maintenance is long and still incomplete.

Although therapeutic options are still limited, effective diagnosis on the clinical and molecular level opens the way to proper treatment. In some cases, targeted therapy is possible such as nucleotide supplementation in the case of patients with TK2 mutations.

Funding This work was supported by National Science Center grant 2014/15/B/NZ5/00434.

Compliance with ethical standards

Ethical approval This article does not contain any studies with human participants performed by any of the authors.

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Ahmed N, Ronchi D, Comi GP (2015) Genes and pathways involved in adult onset disorders featuring muscle mitochondrial DNA instability. Int J Mol Sci 16(8):18054–18076

Antonenkov VD, Isomursu A, Mennerich D, Vapola MH, Weiher H, Kietzmann T, Hiltunen JK (2015) The human mitochondrial DNA depletion syndrome gene MPV17 encodes a non-selective channel that modulates membrane potential. J Biol Chem 290(22):13840–13861

Arpa J, Cruz-Martinez A, Campos Y, Gutiérrez-Molina M, García-Rio F, Pérez-Conde C, Martín MA, Rubio JC, Del Hoyo P, Arpa-Fernández A, Arenas J (2003) Prevalence and progression of mitochondrial diseases: a study of 50 patients. Muscle Nerve 28(6):690–695

Behin A, Jardel C, Claeyx KG, Fagart J, Louha M, Romero NB, Laforet P, Eymard B, Lombes A (2012) Adult cases of mitochondrial DNA depletion due to TK2 defect: an expanding spectrum. Neurology 78:644–648

Bronskaers A, Gago F, Balzarini J, Liekens S (2009) The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med Res Rev 29(6):903–953

Cámara Y, Carreño-Gago L, Martín MA, Melià MJ, Blázquez A, Delmiro A, Garraud G, Moren C, Diaz-Manera J, Gallardo E, Bornstein B, López-Gallardo E, Hernández-Lain A, San Millán B, Cancho E, Rodriguez-Vico JS, Martí R, García-Arumí E (2015) Severe TK2 enzyme activity deficiency in patients with mild forms of myopathy. Neurology 84(22):2286–2288

Campbell C, Kolesar J, Kaufman B (2012) Mitochondrial transcription factor a regulates mitochondrial transcription initiation, DNA packaging, and genome copy number. Biochim Biophys Acta 1819(9–10):921–929

Capps GJ, Samuels D, Chinnery P (2003) A model of the nuclear control of mitochondrial DNA replication. J Theor Biol 221:565–583

Capt C, Passamonti M, Breton S (2016) The human mitochondrial genome may code for more than 13 proteins. Mitochondrial DNA A DNA Mapp Seq Anal 27(5):3098–3101

Cerritelli S et al (2003) Failure to produce mitochondrial DNA results in embryonic lethality in Rnaseh1 null mice. Mol Cell 11:807–815

Chen H, Vermulst M, Wang YE, Chomyn A, Prolla TA, McCaffery JM, Chan DC (2010) Mitochondrial fusion is required for mtDNA stability in skeletal muscle and tolerance of mtDNA mutations. Cell 141(2):280–289

Ciesielkis G, Rosado-Ruiz F, Kaguni L (2016) Purification and comparative assay of human mitochondrial single-stranded DNA-binding protein. Methods Mol Biol 1351:211–222

Delbaški K, Hoff K, Copeland W (2016) Role of the mitochondrial DNA replication machinery in mitochondrial DNA mutagenesis, aging and age-related diseases. Ageing Res Rev 33:89–104

Dinwiddie G, Gaskin D, Chan K, Norrington J, McCleary R (2013) Residential segregation, geographic proximity and type of services used: evidence for racial/ethnic disparities in mental health. Soc Sci Med 80:67–75

DiRe M, Sembongi H, He J, Reyes A, Yasukawa T, Martinsson P, Bailey LJ, Goffart S, Boyd-Kirkup JD, Wong TS, Fersht AR, Spelbrink JN, Holt JI (2009) The accessory subunit of mitochondrial DNA polymerase γ determines the DNA content of mitochondrial nucleoids in human cultured cells. Nucleic Acids Res 37(17):5701–5713

Ekstrand MI, Falkenberg M, Rantananen A, Park CB, Gaspari M, Hultenby K, Rustin P, Gustafsson CM, Larsson NG (2004) Mitochondrial transcription factor a regulates mtDNA copy number in mammals. Hum Mol Genet 13(9):935–944

Elachouri G, Vidoni S, Zanna C, Pattyn A, Boukhaddaoui H, Gaget K, Yu-Wai-Man P, Gasparre G, Sarzi E, Delettre C, Olichon A, Loiseau P, Chinnery PF, Rotig A, Carelli V, Hamel CP, Rugolo M, Lenaers G (2011) OPA1 links human mitochondrial genome mutation and presents as childhood epileptic encephalopathy. Am J Med Genet A 150A:2002–2011

Fahren JD, Liu R, Perry MS, Klein J, Chan DC (2016) A novel de novo dominant negative mutation in DNMT1 impairs mitochondrial fusion and presents as childhood epileptic encephalopathy. Am J Med Genet A 170A:2002–2011

Falkenberg M, Gaspari M, Rantanan A, Trifunovic A, Larsson NG, Gustafsson CM (2002) Mitochondrial transcription factors B1 and B2 activate transcription of human mtDNA. Nat Genet 31:289–294
Filadi R, Grootie T, Turacchio G, Luini A, Pozzan T, Pizzo P (2015) Mitofusin 2 ablation increases endoplasmic reticulum–mitochondria coupling. Proc Natl Acad Sci U S A 112(17):2174–2181

Friedman JR, Lackner LL, West M, DiBenedetto JR, Nunnari J, Voeltz GK (2011) ER tubules mark sites of mitochondrial division. Science 334(6054):358–362

García-Gómez S, Reyes A, Martínez-Jiménez MI, Sandra Chocrón E, Mournón S, Terrados G, Powell C, Salido E, Méndez J, Holt IJ, Blanco L (2013) PrimPol, an archaic Primae/polymerase operating in human cells. Mol Cell 52(4):541–553

Goffari S, Cooper HM, Tynimsaa H, Wanrooj S, Suomalainen A, Sperlbrick JN (2009) Twinkle mutations associated with autosomal dominant progressive external ophthalmoplegia lead to impaired helicase function and in vivo mtDNA replication stalling. Hum Mol Genet 18(2):328–340

Gorman GS, Schaefer AM, Ng Y, Gomez N, Blakely EL, Alston CL, Holt IJ, Lorimer H, Jacobs H (2000) Coupled leading- and lagging-strand helicase function and in vivo mtDNA replication revisited: only TFAM and TFB2M are required for transcription of the mitochondrial genes in vitro. J Biol Chem 285:18129–18133

Liu Y, Wang X, Chen X (2015) Mismatching of mutant adenine nucleotide translocase in yeast supports a novel mechanism of Ant1-induced muscle diseases. Mol Biol Cell 26(11):1985–1994

Lodeiro M, Uchida A, Bestwick M, Moustafa I, Arnold J, Shadel G, Cameron C (2012) Transcription from the second heavy-strand promoter of human mtDNA is repressed by transcription factor a in vitro. Proc Natl Acad Sci U S A 109(17):6513–6518

Losón OC, Song Z, Chen H, Chan DC (2013) Fis1, Mff, MiD49, and MiD51 mediate Drp1 recruitment in mitochondrial fission. Mol Biol Cell 24(5):659–667

MacVicar T, Langer T (2016) OPA1 processing in cell death and disease—the long and short of it. J Cell Sci 129(12):2297–2306

Maier D, Farr C, Poeck B, Alahari A, Vogel M, Fischer S, Kaguni LS, Schnewly S (2001) Mitochondrial single-stranded DNA-binding protein is required for mitochondrial DNA replication and development in Drosophila melanogaster. Mol Biol Cell 12:821–830

Manusco M, Filosto M, Bonilla E (2003) Mitochondrial myopathy of childhood associated with mitochondrial DNA depletion and a homozgyous mutation (T77M) in the TK2 gene. Arch Neurol 60(7):1007–1009

Martin-Garcia J (2013) Mitochondria and their role in cardiovascular disease. In: Introduction to mitochondria in the heart. Springer, Boston, pp 63–65

Mecham E, Oliveira M (2013) Replicating animal mitochondrial DNA. Genet Mol Biol 36(3):308–315

Milenkovic D, Matic S, Kühl I, Ruzzenente B, Freyer C, Jemt E, Park MJ, He J, Duch AM, Griffiths PG, Ahlqvist K, Suomalainen A, Reynier P, McFarland R, Turner DM, McFarland R (2015) Prevalence of nuclear and mitochondrial DNA deletions: a novel disorder of mtDNA maintenance. Brain 138(12):3291–3302

Mouret P, Barrau D, Chibbaro S, Courtin G, Rondelard L, Benyamina M, Saunier N, Lebre P, Benoist C, Ettore R, Henry S, Fournier P, Benoist M, Goulet F, Ruffello F, Alcalay R, Aymard M, Diehl V, Lebrun A, Cadeville J, Heron M, Capeletti M, Kodama Y, Gruart P, Pin A, Mrotek F, Pelon J, Barjon M, Aimo C, Damour T, Gelot A, Kirik D, Martinou JC, Sardet C, Bernard-Pierrot I, Cariou A, Boquenon J, Allamand V, Deleu C, Healy B, Laval G, Doucet B, Carrière S, Cointe B, Gauthier E, Dufour JM, Gaudric P, Schlenker-Meister S, Gendron-Meurice C, Calleja P, Jego L, Faivre A, Lion I, Pouthas V, Kornmann B, Krief P, Pilet-Pelletier V, Guicheney P, Bellon G, Macchi P, Kahn A, Colasanti A, Theil G, Cornu B, Dehoux P, Pugnet M, Pichon L, Robberecht P, Angevin E, Mazières Y, Gérard L, de Caumont A, Fournier P, Rodier F, Le Deist M, Zeviani M (2002) Mutations of mitochondrial DNA polymerase γ are a frequent cause of autosomal dominant or recessive progressive external ophthalmoplegia. Ann Neurol 52:211–219

Lee YS, Kennedy WD, Yin YW (2009) Structural insights into human mitochondrial DNA replication and disease-related polymerase mutations. Cell 139(2):312–324

Lightowers R, Taylor R, Turnbull D (2015) Mutations causing mitochondrial DNA replication stalling: what is new and what challenges remain? Science 349:1494–1499

Linkowska K, Jawień A, Marszalek A, Maryarchuk BA, Toriska K, Bartnik E, Skonieczka K, Z roboticzki T, Zeviani M (2015) Mitochondrial DNA polymerase γ mutations and their implications in mtDNA alterations in colorectal cancer. Ann Hum Genet 79:320–328

Litonin D, Sologub M, Shi Y, Savkina M, Anikin M, Falkenberg M, Gustafsson CM, Temiakov D (2010) Human mitochondrial transcription revisited: only TFAM and TFB2M are required for transcription of the mitochondrial genes in vitro. J Biol Chem 285:18129–18133

Springer
Neckelmann N, Li K, Wade RP, Shuster R, Wallace DC (1987) cDNA sequence of a human skeletal muscle ADP/ATP translocator: lack of a leader peptide, divergence from a fibroblast translocator cDNA, and coevolution with mitochondrial DNA genes. Proc Natl Acad Sci U S A 84(21):7580–7584

Nicholls DJ, Zsurka G, Peeva V, Schöler S, Szczesny RJ, Cywesewski D, Reyes A, Komblum C, Sciacci M, Moggio M, Dziembowski A, Kunz WS, Miniczuk M (2014) Linear mtDNA fragments and unusual mtDNA rearrangements associated with pathological deficiency of MGGME1 exonuclease. Hum Mol Genet 23(23):6147–6162

Nikkanen J, Forsström S, Euro L, Paetau I, Kohnz RA, Wang L, Chilov Paramasivam A, Meena A, Pedaparthi L, Jyothi V, Uppin MS, Jabeen Pebay-Peyroula E, Dahout-Gonzalez C, Kahn R, Trézeguet V, Lauquin Pfeffer G, Pyle A, Griffin H, Miller J, Wilson V, Turnbull L, Fawcett K, Picca A, Lezza A (2015) Regulation of mitochondrial biogenesis through TFAM–Mitochondrial Replicase. Genome Biol Evol 7(4):943–959

Oliveira M, Haukka J, Kaguni L (2015) Evolution of the Metazoan mitochondrial Replicase. Genome Biol Evol 7(4):943–959

Parañas C, Gutierrez Rios P, Rivas E, Carbonell P, Hirano M, DiMauro S (2013) TK2 mutation presenting as indolent myopathy. Neurology 80(50):506

Paramasivam A, Meena A, Pedaparthi L, Jyothi V, Uppin MS, Jabeen SA, Sundaram C, Thangaraj K (2016) Novel mutation in TWNK associated with multiple mitochondrial deletions, chronic progressive external ophthalmoplegia and premature aging. Mitochondrion 26:81–85

Pebay-Peyroula E, Dahout-Gonzalez C, Kahn R, Trézeguet V, Lauquin Pfeffer G, Gornon GS, Griffen H, Kurzawa-Akambi M, Blakely EL, Wilson I, Sitarz K, Moore D, Murphy JL, Alston CL, Pyle A, Coxhead J, Payne B, Gorrie GH, Longman C, Hadijvassiliou M, McConville J, Dick D, Imam I, Hilton D, Norwood F, Baker MR, Jaiser SR, Yu-Wai-Man P, Farewell M, McCarthy A, Lynch T, McFarland R, Schaefer AM, Turnbull DM, Horvath R, Taylor RW, Chimney PF (2014) Mutations in the SPG7 gene cause chronic progressive external ophthalmoplegia through disordered mitochondrial DNA maintenance. Brain 137(Pt 5):1323–1336

Pfeffer G, Pyle A, Griffen H, Miller J, Wilson V, Turnbull L, Fawcett K, Sims D, EGLON G, Hadijvassiliou M, Horvath R, Németh A, Chimney PF (2015) SPG7 mutations are a common cause of undiagnosed ataxia. Neurology 84(11):1174–1176

Pica A, Lezza A (2015) Regulation of mitochondrial biogenesis through TFAM–mitochondrial DNA interactions: useful insights from aging and calorie restriction studies. Mitochondrion 25:67–75

Pontarini G, Ferraro P, Bee L, Reichard P, Bianchi V (2012) Mammalian ribonucleotide reductase subunit p53R2 is required for mitochondrial DNA replication and DNA repair in quiescent cells. Proc Natl Acad Sci U S A 109(33):13302–13307

Posse V, Shahzad S, Falkenberg M, Häfliger M, Gustafsson CM (2015) TEFM is a potent stimulator of mitochondrial transcription elongation in vitro. Nucleic Acids Res 43(5):2615–2624

Reyes A, Melchionda L, Nasca A, Carrara F, Lamantia E, Zanolini A, Lamperti C, Fang M, Zhang J, Ronchi D, Bonato S, Fagiolari G, Moggio M, Ghezzi D, Zeviani M (2015) RNASEH1 mutations impair mtDNA replication and cause adult-onset mitochondrial encephalomyopathy. Am J Hum Genet 97:186–193

Ronchi D, Garone C, Bordoni A, Gutierrezreiz P, Calvo SE, Ripolone M, Ranieri M, Rizzutti M, Villa L, Magri F, Corti S, Bresolin N, Shen B, Comi GP (2013) Mutations in DNA2 link progressive Myopathy to mitochondrial DNA instability. Am J Hum Genet 92(2):293–300

Ruhanen H, Borriea S, Szabadkaibe G, Tynishmaa H, Jones A, Kange D, Taanmande JW, Yasukawa T (2010) Mitochondrial single-stranded DNA binding protein is required for maintenance of mitochondrial DNA and 7S DNA but is not required for mitochondrial nucleoid organization. Biochim Biophys Acta (BBA) Mol Cell Res Vol 1803(8):931–939

Saada A, Shaag A, Mandel H, Nevo Y, Eriksson S, Elpeleg O (2001) Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. Nat Genet 29:342–344

Sánchez-Ferrero E, Coto E, Beetz C, Gómez J, Corao Al, Díaz M, Esteban J, del Castillo E, Moris G, Infante J, Menéndez M, Pascual-Pascual SL, López de Munain A, García-Barcina MJ, Alvarez V (2013) SPG7 mutational screening in spastic paraplegia patients supports a dominant effect for some mutations and a pathogenic role for p.A510V. Clin Genet 83:257–262

Schatz G (1963) The isolation of possible mitochondrial precursor structures from aerobically grown baker’s yeast. Biochem Biophys Res Commun 12:448–451

Scheibye-Knudsen M, Fang EF, Croteau DL, Wilson DM, Bohr VA (2015) Protecting the mitochondrial powerhouse. Trends Cell Biol 25(3):158–170

Shokolenko I, Alexeyev M (2015) Mitochondrial DNA: a disposable genome? Biochim Biophys Acta (BBA) Mol Basis Dis 1852:1805–1809

Składal D, Halliday J, Thorburn DR (2003) Minimum birth prevalence of mitochondrial respiratory chain disorders in children. Brain 126:1905–1912

Spinazzola A, Viscomi C, Fernandez-Vizarra E, Carrara F, D’Adamo P, Calvo S, Marsano RM, Domini C, Wehrer H, Strisciuglio P, Parini R, Sarzi E, Chan A, DiMauro S, Rötig A, Gasparini P, Ferrero I, Mootha VK, Tiranti V, Zeviani M (2006) MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion. Nat Genet 38:570–575

Stiles AR, Simon MT, Stover A, Effekharian S, Khanou N, Wang HL, Magaki S, Lee H, Partynski K, Dorrani N, Chang R, Martinez-Agosto JA, Abdenur JE (2016) Mutations in TFAM, encoding encoding mitochondrial thymidine transcription factor a, cause neonatal liver failure associated with mtDNA depletion. Mol Genet Metab 119:91–99

Suomalainen A, Isohanni P (2010) Mitochondrial DNA depletion syndromes – many genes, common mechanisms. Neuromuscul Disord 20:429–437

Szymanski MR, Kuznetsov VB, Shumate C, Meng Q, Lee YS, Patel G, Patel S, Yin YW (2015) Structural basis for processivity and antiviral drug toxicity in human mitochondrial DNA replicase. EMBO J 34(14):1959–1970

Tyynismaa H, Sembongi H, Bokori-Brown M, Granycome C, Ashley N, Poulton J, Jalanko A, Spelbrink JN, Holt II, Suomalainen A (2004) Twinkle helicase is essential for mtDNA maintenance and regulates mtDNA copy number. Hum Mol Genet 13(24):3219–3227

Tyynismaa H, Peltola K, Wanrooj S, Lappalainen I (2005) Mutant mitochondrial helicase Twinkle causes multiple mtDNA deletions and a late-onset mitochondrial disease in mice. Proc Natl Acad Sci U S A 102(49):17687–17692

Tyynismaa H, Sun R, Ahola-Erkkilä S, Almusa H, Pöyhönen R, Korpela Jaiser SR, Yu-Wai-Man P, Farrell M, Lynch T, McConville J, Dick D, Imam I, Hilton D, Norwood F, Baker MR, Jaiser SR, Yu-Wai-Man P, Farewell M, McCarthy A, Lynch T, McFarland R, Schaefer AM, Turnbull DM, Horvath R, Taylor RW, Chimney PF (2014) Mutations in the SPG7 gene cause chronic progressive external ophthalmoplegia through disordered mitochondrial DNA maintenance. Brain 137(Pt 5):1323–1336
Van Dyck E, Foury F, Stillman B, Brill SJ (1992) Single-stranded DNA binding protein required for mitochondrial DNA replication in S. cerevisiae is homologous to E. coli SSB. EMBO 11:3421–3430

Vielhaber S, Debska-Vielhaber G, Peeva V, Schoeler S, Kudin AP, Minin I, Schreiber S, Dengler R, Kollewe K, Zscharratter W, Komblum C, Zsurka G, Kunz WS (2013) Mitofusin 2 mutations affect mitochondrial function by mitochondrial DNA depletion. Acta Neuropathol 125(2):245–256

Wang L, Saada A, Eriksson S (2003) Kinetic properties of mutant human thymidine kinase 2 suggest a mechanism for mitochondrial DNA depletion myopathy. J Biol Chem 278:6963–6968

Wong LJ (2013) Next generation molecular diagnosis of mitochondrial disorders. Mitochondrion 13:379–387

Wortmann SB, Koolen DA, Smetink JA, van den Heuvel L, Rodenburg RJ (2015) Whole exome sequencing of suspected mitochondrial patients in clinical practice. J Inherit Metab Dis 38(3):437–443

Yoon G, Malam Z, Paton T, Marshall CR, Hyatt E, Ivakine Z, Scherer SW, Lee KS, Hawkins C, Cohn RD (2016) Lethal disorder of mitochondrial fission caused by mutations in DNM1L. J Pediatr 171:313–316

Young M, Copeland W (2016) Human mitochondrial DNA replication machinery and disease. Curr Opin Genet Dev 3:52–62

Yu-Wai-Man P, Griffiths PG, Gorman GS, Lourenco CM, Wright AF, Auer-Grumbach M, Toscano A, Musumeci O, Valentino ML, Caporali L, Lamperti C, Tallaksen CM, Duffey P, Miller J, Whittaker RG, Baker MR, Jackson MJ, Clarke MP, Dhillon B, Czermin B, Stewart JD, Hudson G, Reynier P, Bonneau D, Marques W Jr, Lenaers G, McFarland R, Taylor RW, Turnbull DM, Votruba M, Zeviani M, Carelli V, Bindoff LA, Horvath R, Amati-Bonneau P, Chinnery PF (2010) Multi-system neurological disease is common in patients with OPA1 mutations. Brain 133(Pt 3):771–786